A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin)[PACOX] in advanced hepatocellular carcinoma patients

2021 ◽  
Author(s):  
Thomas Yau ◽  
Paul N. M. Cheng ◽  
Joanne Chiu ◽  
Gerry Gin Wai Kwok ◽  
Roland Leung ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systemic Chemotherapy ◽  
Phase 1 ◽  
Advanced Hepatocellular Carcinoma ◽  
Phase 1 Study

Phase 1 study of N 1,N 11-diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma

2013 ◽  
Vol 72 (6) ◽  
pp. 1305-1314 ◽  
Author(s):  
Lipika Goyal ◽  
Jeffrey G. Supko ◽  
Jordan Berlin ◽  
Lawrence S. Blaszkowsky ◽  
Amanda Carpenter ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Phase 1 ◽  
Advanced Hepatocellular Carcinoma ◽  
Phase 1 Study

Personalised peptide vaccination combined with radiotherapy for patients with advanced hepatocellular carcinoma: a phase 1 study

2017 ◽  
Vol 18 ◽  
pp. S5
Author(s):  
Jie Shen ◽  
Zheng-Yun Zou ◽  
Li-Feng Wang ◽  
Jing Yan ◽  
Wei-Wei Kong ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Phase 1 ◽  
Advanced Hepatocellular Carcinoma ◽  
Peptide Vaccination ◽  
Phase 1 Study

ADI-PEG 20 and FOLFOX6: A phase 1 study in pts (pts) with advanced hepatocellular carcinoma (HCC).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 4085-4085
Author(s):  
James J. Harding ◽  
Richard K. G. Do ◽  
Ellen Hollywood ◽  
Khrystyna Uhlitskykh ◽  
Emily Valentino ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Phase 1 ◽  
Advanced Hepatocellular Carcinoma ◽  
Phase 1 Study

scholarly journals A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies

2018 ◽  
Vol 82 (3) ◽  
pp. 429-440 ◽  
Author(s):  
James J. Harding ◽  
Richard K. Do ◽  
Imane El Dika ◽  
Ellen Hollywood ◽  
Khrystyna Uhlitskykh ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Phase 1 ◽  
Advanced Hepatocellular Carcinoma ◽  
Phase 1 Study ◽  
Gastrointestinal Malignancies ◽  
Modified Folfox6

scholarly journals Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

The Lancet ◽  
2017 ◽  
Vol 389 (10088) ◽  
pp. 2492-2502 ◽  
Author(s):  
Anthony B El-Khoueiry ◽  
Bruno Sangro ◽  
Thomas Yau ◽  
Todd S Crocenzi ◽  
Masatoshi Kudo ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Dose Escalation ◽  
Phase 1 ◽  
Advanced Hepatocellular Carcinoma ◽  
Open Label

Phase 1 study of intra-arterial hepatic (IAH) delivery of doxorubicin-transdrug (DT) for patients with advanced hepatocellular carcinoma (HCC)

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14094-14094 ◽  
Author(s):  
P. Merle ◽  
S. Si Ahmed ◽  
F. Habersetzer ◽  
A. Abergel ◽  
J. Taieb ◽  
...  
Keyword(s):  
Adverse Events ◽  
Distress Syndrome ◽  
Phase 1 ◽  
Advanced Hepatocellular Carcinoma ◽  
Contrast Injection ◽  
Phase 1 Study ◽  
Serious Adverse Events ◽  
Advanced Hcc ◽  
Arterial Perfusion ◽  
Cirrhotic Patients

14094 Background: HCC is a highly chemoresistant due to MDR efflux pumps. DT is a newly cytotoxic chemotherapy composed of doxorubicin-loadded polyisohexylcyanoacrylate nanoparticles, allowing doxorubicin to overcome MDR pumps [Barraud, J Hepatol 2005; 42: 736]. Methods: 16 cirrhotic patients (pts) of Child-Pugh A with advanced HCC, transaminases/GGT <5N, platelets >100000/mm3, neutrophiles >1500/mm3, were enrolled in a multicentric noncontrolled study. A single IAH injection of 10, 20, 30, 35, or 40mg/m2 DT (respectively 3,3,4, and 3 pts) was performed, tolerance and efficacy being assessed 4 weeks later. Results: Grade 4 neutropenia (2pts at 40mg/m2) gave the Maximal Tolerated Dose. Grade 2–3 hypertransaminasemia (transient) occurred dose-independently. Two serious adverse events (SAE) were hypotension and acute respiratory distress syndrome. All adverse events (AE) (90% grade 1–2) occurring during injection were dose-independent, and completely and fastly recovered : cough (6pts), dyspnea (2pts), SaO2 decrease (2pts), tachycardia (2pts), bradycardia (2pts), hypotension (2pts). Anti-tumor efficacy of DT was evaluated by helicoidal CT-scan with contrast injection 4 weeks after injection : 3pts (20%) showed partial response with frank decrease of contrast enhancement at arterial perfusion, 8pts (50%) remained stable, and 5pts (30%) had progression. Conclusions: This phase 1 showed that a single IAH injection of DT was safe until 35 mg/m2 for Child-Pugh A patients with advanced HCC. This dosage will be retained for the phase 2 step comprising 3 injections at 4-week intervals which will aim at confirming the antitumour efficacy of DT for HCC. [Table: see text]

Phase 1 study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC): Correlation of tumor and serum biomarker data with disease control.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 4095-4095
Author(s):  
Matteo Simonelli ◽  
Crystal Shereen Denlinger ◽  
Laura Williams Goff ◽  
Cristina Noberasco ◽  
Tae-You Kim ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Disease Control ◽  
Phase 1 ◽  
Serum Biomarker ◽  
Phase 1 Study ◽  
Biomarker Data
Sign in / Sign up

Export Citation Format

Share Document